ArticleDiscover oncology2025
Mapping the landscape: a comprehensive bibliometric analysis of immunotherapy advances in glioblastoma research.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-cell transcriptomics in metastatic breast cancer: mapping tumor evolution and therapeutic resistance.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a poor prognosis largely due to its immunosuppressive microenvironment. Immunotherapy offers a promising approach by targeting this barrier to anti-tumor immunity. Despite growing research interest, an overview of the field's development is still lacking. This study uses bibliometric analysis to map trends and key advances in GBM immunotherapy research from 2005 to 2024.
methodsA systematic bibliometric search was performed in the Web of Science Core Collection from 2005 to 2024, using a predefined search strategy combining terms related to "glioblastoma" and "immunotherapy". Only peer-reviewed articles and reviews in English were included. Bibliometric analysis was conducted using VOSviewer, CiteSpace, and Scimago Graphica to visualize research trends and collaboration networks.
resultsFrom 2005 to 2024, a total of 2064 publications on GBM immunotherapy were identified, with China and the United States as the leading contributors. Co-citation analysis highlighted Roger Stupp as the most influential author, while Frontiers in Oncology was the most prolific journal. Keyword burst analysis revealed increasing clinical interest in nivolumab and chemotherapy, with neoadjuvant immunotherapy emerging as a promising research direction.
conclusionsThe analysis of 2,064 publications on GBM immunotherapy highlights a high level of collaborative effort aimed at advancing novel therapeutic approaches. The findings emphasize the importance of the tumor microenvironment and suggest that future efforts should focus on overcoming immune suppression and developing targeted combination therapies. This study provides a useful reference for guiding research and improving immunotherapy strategies in GBM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.